The Royal College of Obstetricians and Gynaecologists (RCOG) have called for action from government and pharmaceutical companies to address ongoing issues with the supply of hormone replacement therapy (HRT). Thousands of people use HRT to help manage menopausal symptoms.

A meeting between RCOG and the government has been agreed but the RCOG says this must happen as a matter of urgency. The RCOG has also called on the Department of Health and Social Care to make a stronger intervention.  

 “What we have got to do is try and work together as professionals with the Department of Health and get these companies to be accountable – give us an explanation,” said Lesley Regan, president of the RCOG. “Firstly, of what the problem is, and most importantly of the timelines before they will be resolved.”

Pharmaceutical companies are struggling to cope with demand. “So far this year, demand for Evorel products in the UK has already exceeded that of the whole of 2018, depleting all surplus stock,” said a spokesperson for Janssen. “As a result, we are unfortunately anticipating a complete interruption to supply across the product range from October 2019, although certain patches may stock out earlier than this date, due to challenges in maintaining our supply to meet this increased demand. We are working on a return to full supply by mid-2020.”

Those using HRT are advised to discuss alternative options with their doctor while the issues are being resolved.